Hanne Skomedal
Avdelingsleder
Forfattere
Maria Hayes Leen Bastiaens Luisa Gouveia Spyros Gkelis Hanne Skomedal Kari Skjånes Patrick Murray Marco García-Vaquero Muge Isleten Hosoglu John Dodd Despoina Konstantinou Ivo Safarik Graziella Chini Zittelli Vytas Rimkus Victόria del Pino Koenraad Muylaert Christine Edwards Morten Laake Joana Gabriela Laranjeira da Silva Hugo Pereira Joana AbelhoSammendrag
Det er ikke registrert sammendrag
Forfattere
Mihaela-Olivia Dobrica Catalin Lazar Lisa Paruch Hanne Skomedal Hege Særvold Steen Sissel Haugslien Catalin Tucureanu Iuliana Caras Adrian Onu Sonya Ciulean Alexandru Branzan Jihong Liu Clarke Crina Stavaru Norica Branza-NichitaSammendrag
Chronic Hepatitis B Virus (HBV) infection leads to severe liver pathogenesis associated with significant morbidity and mortality. As no curable medication is yet available, vaccination remains the most costeffective approach to limit HBV spreading and control the infection. Although safe and efficient, the standard vaccine based on production of the small (S) envelope protein in yeast fails to elicit an effective immune response in about 10% of vaccinated individuals, which are at risk of infection. One strategy to address this issue is the development of more immunogenic antigens. Here we describe a novel HBV antigen obtained by combining relevant immunogenic determinants of S and large (L) envelope proteins. Our approach was based on the insertion of residues 21-47 of the preS1 domain of the L protein (nomenclature according to genotype D), involved in virus attachment to hepatocytes, within the external antigenic loop of S. The resulting S/preS121-47 chimera was successfully produced in HEK293T and Nicotiana benthamiana plants, as a more economical recombinant protein production platform. Comparative biochemical, functional and electron microscopy analysis indicated assembly of the novel antigen into subviral particles in mammalian and plant cells. Importantly, these particles preserve both S- and preS1-specific epitopes and elicit significantly stronger humoral and cellular immune responses than the S protein, in both expression systems used. Our data promote this antigen as a promising vaccine candidate to overcome poor responsiveness to the conventional, S protein-based, HBV vaccine.
Forfattere
M. Hayes Hanne Skomedal Kari Skjånes H. Mazur-Marzec A. Torunska-Sitarz M. Catala M. Isleten Hosoglu M. García-VaqueroSammendrag
Det er ikke registrert sammendrag
Sammendrag
Det er ikke registrert sammendrag
Sammendrag
Det er ikke registrert sammendrag
Forfattere
Jihong Liu Clarke Johanna Gottschamel Hege Særvold Steen Sissel Haugslien Hanne Skomedal Andreas G. Lössl Stephanie Ruf Ralph BockSammendrag
Det er ikke registrert sammendrag
Divisjon for bioteknologi og plantehelse
Algae to Future (A2F) From Fundamental Algae Research to Applied Industrial Practices
Divisjon for bioteknologi og plantehelse
Algae to Future (A2F) - Alger for fremtiden
Med mikroalger som utgangspunkt vil forskerprosjektet «Alger for fremtiden - A2F» undersøke algenes potensial til å produsere høykvalitets proteiner, flerumettede fettsyrer og karbohydrater til fremtidens matfat. Vi vil kombinere fagkunnskap om dyrking og optimalisering av mikroalgers biomassekomposisjon i lab- og pilotskala, med erfaringen til bl.a. profesjonelle bakere, ølbryggere og fiskefôrprodusenter. Slik legger vi grunnlaget for en felles innovasjonsplattform for fremtidens bærekraftige norske algeindustri.